Inventiva S.A. (NASDAQ:IVA) Q2 2022 Earnings Conference Call September 22, 2022 8:00 AM ET

Company Participants

Frédéric Cren - Co-Founder and CEO

Pierre Broqua - Co-Founder and CSO

Michael Cooreman - Chief Medical Officer

Jean Volatier - Chief Financial Officer

Philip Duong - Head, Investment

Conference Call Participants

Ed Arce - H.C. Wainwright

Jeroen Van den Bossche - KBC Securities

Alex Cogut - Bryan, Garnier

Delphine Le Louët - Société Générale

Operator

Good day and thank you for standing by. Welcome to the Inventiva 2022 Half Year Results and Webcast. At this time, all participants are in listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions]

Please note that today’s conference is being recorded. I would now like to hand over to your speaker, Mr. Frédéric Cren, CEO and Co-Founder. Please go ahead.

Frédéric Cren

Thank you, and welcome, everybody, to this half year webcast. As usual, some disclaimer, we will be making forward-looking statements. So please have a look at our regulatory filings that are available on our website.

In terms of speakers, I would say, we have the classical imperative team, myself and Pierre, the Co-Founder of the company; with Michael, our CMO; and Jean, our CFO. But today, it’s a special day for Inventiva given the recent partnership we signed with Sino Biopharm lanifibranor. We are very pleased to have with us Philip Duong, Head of Investment, who will give us an overview of Sino Biopharm activity.

In terms of agenda, I will give an highlight of the activity over the past six months and then I will share the floor with Philip, with Pierre, with Michael to provide a pipeline update. We will move to the financial section with Jean, near-term catalyst and then we will open the floor for Q&A.

So moving now to the highlight section, we will start first with lani, our Phase III drug in non-alcoholic steatohepatitis, NASH. Importantly, a lot of improvement, a lot of key important milestones has been reached in the past six months.

In terms of NATiV3, we have expanded in 24 countries and we have now activated to 300 sites in the trial and in the presentation, we will give you a bit more detail on the improvement in terms of site.

Very pleased, as I mentioned in my introduction of the very recent collaboration with signing with Sino Biopharm and the expansion of lani in Greater China, a country that we see is really promising from a commercial point of view, given the prevalence of NASH among the Chinese population.